BIOADAPTIVES, INC.

Public

Las Vegas, NV

Visit website

Latest valuation

—

No round has disclosed a priced valuation or cap.

Total raised

$200,000

Across 1 round since 2022

Latest share price

$0.0075

Reg A Offering (2022) offering price

Financials

FY2013–FY2025 (no data for FY2016, FY2017) · from SEC filings · hover any figure for its source

−$1.4M

2018

$10K

−$239K

2019

$16K

−$847K

2020

$20K

−$1.0M

2021

$17K

−$896K

2022

$29K

−$712K

2023

$13K

−$899K

2024

$18K

−$1.6M

2025

RevenueNet income — beside revenue when positive, below the line when a loss

Chart shows the most recent 8 fiscal years; 3 earlier years are in the table below.

Metric

FY2013 audited

FY2014 audited

FY2015 audited

FY2018 audited

FY2019 audited

FY2020 audited

FY2021 audited

FY2022 audited

FY2023 audited

FY2024 audited

FY2025 audited

Income statement

Revenue

—

$9,934

$16,327

$19,776

$17,176

$28,565

$12,669

$18,278

Cost of goods sold

—

$5,049

$10,232

$9,671

$10,050

$17,746

$8,639

$5,781

Gross margin

—

49%

37%

51%

41%

38%

32%

68%

Net income

—

-$2,575,433

-$227,432

-$1,406,663

-$238,927

-$847,244

-$1,049,948

-$895,570

-$712,466

-$899,161

-$1,557,898

Taxes paid

—

Balance sheet

Cash

$18,609

$37,871

$99

$56,215

$12,313

$4,587

$82,936

$25,405

$60,776

$261,885

$215,205

Accounts receivable

—

Total assets

$120,309

$70,761

$7,190

$110,059

$24,213

$18,846

$148,585

$37,314

$103,998

$261,885

$225,901

Short-term debt

—

$7,218

—

Long-term debt

—

Total liabilities

—

$70,878

$210,564

$803,800

$864,089

$1,397,631

$1,241,624

$1,488,815

$1,750,629

$1,725,803

$2,355,957

Other

Headcount

—

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Fundraising history

Reg A Offering (2023)AbandonedReg A+ · Debt

Raised $0 / $200K

Reg A Offering (2022)ClosedReg A+ · Equity

Raised $200K / $1.5M

Team

3 people

Edward E. Jacobs, Jr., MD

Director and Chief Executive Officer

Charles Townsend

Director, Chief Operating Officer

Robert W. Ellis

Director and President

Names and titles as disclosed on SEC Form 1-A. Bios and photos come from the platform campaign page and may be out of date.

SEC filings

View all 48 filings on EDGAR

Form 10-QAug 19, 20260001640334-26-001393
EDGAR
Form 10-QMay 15, 20260001640334-26-000911
EDGAR
Form 10-KApr 14, 20260001640334-26-000718
EDGAR
Form 10-QNov 14, 20250001640334-25-002081
EDGAR
Form 10-QAug 14, 20250001640334-25-001493
EDGAR
Form 10-QMay 13, 20250001640334-25-000834
EDGAR
Form 10-KApr 15, 20250001640334-25-000660
EDGAR
Form 10-QNov 19, 20240001640334-24-001752
EDGAR

Source: SEC EDGARCIK 0001575142DEShare price $0.0075Last synced Aug 16, 2026

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.